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Summary: We measured the carboxyl-terminal immunoreactive parathyrin (parathyroid Hormone) in samples
from twenty catheterized patients with hypertension. The radioimmunoassay reacted equally well with intact
parathyrin and carboxyl-terminal parathyrin fragments. The renal arterio-venous extraction ratio (extraction
ratio = arterio-venous concentration difference divided by the arterial concentration) of endogenous carb-
oxyl-terminal immunoreactive parathyrin equalled that of inulin, with mean values for both of 0.17. The
carboxyl-terminal parathyrin fragments have about the same molecular weight äs inulin, and they are extract-
ed exclusively by glomerular filtration, whereas intact parathyrin is extracted by both peritubular uptake and
glomerular filtration. The findings therefore agree with a high proportion of circulating carboxyl-terminal
parathyrin fragments in normal man. The mean extraction ratio of endogenous carboxyl-terminal immuno-
reactive parathyrin across riine livers was 0.16. Some of the hepatic extraction might be due to cleavage and
uptake of intact parathyrin, which constitütes about 15% of the circulating immunoreactive parathyrin, but
the findings suggest that the liVer also extracts and metabolizes the circulating carboxyl-terminal parathyrin
fragments in normal man.
Renale und hepatische Extraktion von carboxyterminalem immunreaktiven Parathyrin bei Gesunden
Zusammenfassung: Carboxyterminales immunreaktives Parathyrin wurde in Proben von zwanzig katheteri-
sierten Patienten mit Hypertonie gemessen. Der Radioimmunassay reagierte gleichgut mit intaktem Para-
thyrin und seinen cärboxyterminaleq Fragmenten. Die renale Extraktion (arteriovenöse Konzentrationsdiffe-
renz, dividiert durch arterielle Konzentration) von endogenem carboxyterminalen immunreaktiven Parathy-
rin glich der von Inulin mit Mittelwerten für beide von 0,17. Die carboxyterminalen Fragmente von Parathy-
rin haben etwa dieselbe relative) Molekülmasse wie Inulin, und sie werden ausschließlich durch glomeruläre
Filtration extrahiert, während intaktes Parathyrin sowohl durch peributuläre Aufnahme als auch durch glo-
meruläre Filtration extrahiert wird. Die Ergebnisse stimmen deshalb mit einem hohen Anteil von zirkulie-
renden carboxyterminalen Parathyrinfragmenten bei Gesunden überein. Der mittlere Extraktionswert für
endogenes carboxyternainales immunreaktives Parathyrin durch neun Lebern betrug 0,16. Ein Teil davon
könnte durch Spaltung und Aufnahme von intaktem Parathyrin bedingt sein, das etwa 15% des zirkulie-
renden immunreaktiven Parathyrins beträgt. Die Ergebnisse deuten aber auch darauf hin, daß die Leber beim
Gesunden ebenfalls zirkulierende carboxyterrninale Parathyrinfragmente extrahiert und verstoffwechselt.
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Introduction
Parathyrin (parathyroid Hormone) is synthesized in
the chief cells of the parathyroid glands, äs part of a
larger polypeptide with 115 amino acids. A 25 ami-
no acid sequence is removed from the amino-termi-
nal end äs the molecule enters the rough endoplas-
matic reticulum, and a further cleavage with removal
of six amino-terminal amino acids occurs in the Gol-
gi complex, resulting in the formation of the intact
hormone with 84 amino acids (1). The secreted hor-
mone is probably cleaved by the reticüloendothelial
System (the Kupffer cells) of the liver into two poly-
peptides, a biologically inactive carboxyl-terminal
fragment, and an amino-terminal fragment with all
the biological activity of the intact hormone (2—6).
Some fragments may also be secreted by the para-
thyroid glands (7), but the importance of this source
is uncertain in normal man. The carboxyl-terminal
fragments haye higher plasma concentrations than
the amino-regibn of the molecule, and assays which
determine carboxyl-terminal immunoreactive para-
thyrin in serum are both specific and sensitive for the
diagnosis of parathyroid disease (l, 8—11). We
wanted to investigate the renal and hepatic extrac-
tion of the endogenous carboxyl-terminal immuno-
reactive parathyrin from the circulation in normal
subjects.
Patients and Methods
We examined twenty patients with hypertension of suspected re-
novascular origin, who had a diagnostic renal vein catheterization.
Nine men and eleven women with a mean age of 49 years gave
their informed consent and allowed us to take some extra blood
samples from the kidneys and the liver. We obtained sämples
from the hepatic vein in nine patients. None of the patients re-
ceived drugs known to alter calcium metabolism. Eleven of the
patients had a renal artery Stenosis and two had a unilateral con-
tracted kidney, but otherwise the only diagnosis was essential hy-
pertension.
Inulin was infused for at least 30 min into an arm vein, before the
catheterization was made via the femoral vein. The patient was
lying on an X-ray bed, and the placing of the catheter was moni-
tored by small injections of Urografin®, 60% ')· The blood was
simultaneously withdrawn from a peripheral artery and the vein of
each organ. Inulin was determined according to Bojesen (12), and
creatinine was determined by the picrate method using continuous
flow analysis.
The carboxyl-terminal immunoreactive parathyrin was measured
by radioimmunoassay with a rabbit anti-bovine-parathyrin antise-
rum specific for the carboxyl-terminal region of parathyrin (Insti-
tut National des Radioelements, Fleurus, Belgium). 125I labelled
intact bovine parathyrin was used äs tracer, and intact bovine pa^·
rathyrin äs Standard. The assay was calibrated with International
Reference Preparation 71/324 which contains l g or 2 IU intact
bovine parathyrin per ampoule. The carboxyl-terminal immuno-
reactive parathyrin consists of both intact parathyrin and carbox-
yl-terminal parathyrin fragments, and cross-reactivity studies in-
dicate that the antiserum reacts equally well with both forms of
parathyrin.
• r
The extraction ratip was the arterio-venous concentration differ-
ence divided by the arterial concentration. We calculated a hypo-
thetical half-life in a normal person äs In 2/A, with a rate constant
k based on the observed extraction ratios, normal rates of plasma
flow, and a one-compartment extracellular volume of distribution
of 141. We compaired paired data by the paired i-test.
Results
The plasma concentrations of carboxyl-terminal im-
munoreactive parathyrin in the artery and vein of
each orgari are shown in figure 1. The mean renal
extraction ratio of carboxyl-terminal immunoreac-
tive parathyrin was 0.172 with a SEM of 0.018. The
mean hepatic extraction ratio of carboxyl-terminal
immunoreactive parathyrin was 0.161 with a SEM of
0.067.
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Fig. l .
') Urografin is a mixture of sodium diatrizoate and methylgluc-
amine diatrizoate.
The plasma concentrations of endogenous carboxyl-termi-
nal immunoreactive parathyrin from the artery and vein of
fofty kidneys and nine livers. The mean plasma concefiträ-
tiön of carboxyKterminal immunoreaetive parathyrin in
the renal artery and vein was 4.95 and 4.09 IU/1, respec-
tively (p < 0.001 by paired r-test), and in the hepatic ar*
tery and vein it was 5.32 and 4.32 IU/1, respectively (p <
0.02 by paired Mest).
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The mean renal extraction ratio of inulin was 0.173
with a SEM of 0.013. The renal extraction ratio of
carboxyl-terminal immunoreactive parathyrin and
that of inulin did not differ, and they were positively
correlated (r = 0.41, p < 0.01). The patients had a
inean clearance of creatinine of 72 ml/min (ränge 39
to 111 ml/min).
Bovine and human parathyrin showed complete
cross-reactivity, and the N./.ß.S.C. Research Stan-
dard for human parathyrin for immunoassay gave
the assigned value (13). Our reference interval for
carboxyl-terminal immunoreactive parathyrin is 2.4
to 6.4 IU/1. The within-assay imprecision (SD) in
normal samples was 0.30 IU/1 (CV = 6%). In a com-
parison between our assay and that of Medi-Lab
A/S, Copenhagen (laboratory no. 15 in I.e. (13)), 39
out of 46 patients' samples were concordantly cate-
gorized äs normal (n = 14) or above normal (AI =
25), and r = 0.92. Three patients with iatrogenic and
one with idiopathic hypoparathyroidism had values
below 2.0 IU/1.
Biscussion
Studies on animals have indicated that the kidneys
extract parathyrin and amino-terminal parathyrin
fragments by glomerular filtration and peritubular
uptake, whereas the carboxyl-terminal parathyrin
fragments are extraeted by glomerular filtration only
(5, 14-16). These experimental results have been
confirmed by cätheterization of hyperparathyroid
patients. Corvilain et al. (17) observed a higher renal
extraction ratio of endögenous amino-terminal im-
munoreactive parathyrin (0.44) than of carboxyl-
terminäl immunoreäctive parathyrin (0.09) in hyper-
parathyroid patients, and Oldham et al. (18) found
an intermediate valüe (0.34) with an amino-terminal
antiserum against predominantly intact parathyrin.
We observed a mean renal extraction ratio of car·^
boxyl-terminal immunoreactive parathyrin of 0.17 iri
normal man, which was identical to that of inulin.
Dambacher et al. (19) found that only about 15% of
the circuläting immunoreactive parathyrin in nor-
mals was intact parathyrin, and the rest was carbox-
yl-terminal parathyrin fragments. In patients with
chronic renal insufficiency they found that only
about 2% of the circul'ating immunoreactive para-
thyrin was intact parathyrin. Some of our subjects
had a slightly reduced renal function, which may
have caused a moderate increase in the concentra-
tion of circulating carboxyl-terminal parathyrin frag-
ments. The carboxyl-terminal parathyrin fragments
have about the same molecular weight äs inulin, and
both substances are freely filtered and eliminated ex-
clusively by glomerular filtration in the kidneys. The
findings are therefore in accord with a large propor-
tion of circulating carboxyl-terminal parathyrin frag-
ments in normal man.
The observed renal extraction ratio of carboxyl-ter-
minal immunoreactive parathyrin and inulin agrees
with a large proportion of carboxyl-terminal para-
thyrin fragments, but the substance ratio between in-
tact parathyrin and its fragments was not deter-
mined. The antiserum we used was specific for the
carboxyl-terminal region of parathyrin, and it react-
ed equally well with intact parathyrin and the car-
boxyl-terminal parathyrin fragments. Animal studies
have suggested that the carboxyl-terminal parathyrin
fragments are not eliminated in the liver, and that
the intact parathyrin molecule is cleaved with the
subsequent release of a carboxyl-terminal parathyrin
cleavage product into the hepatic venous circulation
(3). However, the experimental model uses injection
or infusion of bovine parathyrin into dogs, and the
results do not necessarily apply to normal man. With
only a small fraction of the circulating immunoreac-
tive parathyrin being intact parathyrin, cleavage
alone could not explain the observed hepatic extrac-
tion of carboxyl-terminal immunoreactive parathyr-
in. We therefore suggest that the liver in addition
extracts and metabolizes the circulating carboxyl-
terminal parathyrin fragments.
The liver receives most of its blood supply from the
portal vein, but we used blood from the hepatic ar-
tery and vein. The lower concentration in the hepatic
vein might therefore be due to mixing with portal
venous blood, if the concentration of carboxyl-ter-
minal immunoreactive parathyrin was lower in the
portal vein. However, Moosa et al. (20) did not find
a lower concentration of carboxyl-terminal immuno-
reactive parathyrin in the portal vein than in the ex-
ternal jugular vein in patients undergoing abdominal
surgery. The low overall clearance of carboxyl-ter-
minal immunoreactive parathyrin in uraemia does
not exclude a hepatic extraction of the carboxyl-ter-
minal parathyrin fragments in normals, because the
renal insufficiency itself may impair the hepatic met-
abolism (14, 21).
We were confined to the investigation of patients
with hypertension, because the present study alone
did not justify the risk of a cätheterization in healthy
individuals. The calculated hypothetical half-life of
carboxyl-terminal immunorective parathyrin in a
normal person was 40 min. This agrees with the
value obtained in hyperparathyroid patients after
subtotal parathyroidectomy (22).
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